venBio Global Strategic Fund IV, L.P.
Follow-ons only
Follow-ons only: first sale Apr 2021, per Form D (fund age approximates vintage)
- Vintage
- 2021
- Fund size
- $549.94M to $550M (Form D)
- Stages
- Not stated
- Sectors
- Biotech
- Regions
- Not stated
01 · Thesis
No thesis found on the firm's website yet.
02 · Initial check
$5.5M to $9.17M (estimated from fund size)
Estimated from Form D: $549.94M sold of a $550M target
03 · Who to approach
Named on this fund's Form D
- Richard Gaster, MD, PhD, Managing Partner
- David Pezeshki, CFA, CPA, Chief Financial Officer
- Aaron Royston, MD, MBA, Managing Partner
- Robert Adelman, MD, Co-founder and Emeritus Managing Partner
- Corey Goodman, PhD, Co-founder and Managing Partner
04 · Deals
No deals attributed to this fund yet.
05 · Evidence
Firm-wideVenbio Partners is a life sciences investment firm focused on novel therapeutics for unmet medical needs.
We are a life sciences investment firm partnering with industry leaders to build game-changing medicines and technologies with a focus on novel therapeutics for unmet medical needs.
https://www.venbio.com/
06 · Sources
Last verified: Oct 28, 2026